Adalvo acquires its first branded product, Onsolis

Adalvo, a global pharmaceutical company, announced today that it has entered into a transaction with a reputable US specialty pharmaceutical company to acquire its first branded product, Onsolis®.The American pharmaceutical company is the original owner of the product.

This brand is an opioid analgesic indicated for the management of persistent breakout pain in cancer patients who have received and tolerated opioid therapy for underlying cancer pain.Adalvo will become the sole and exclusive owner of the brand and will acquire full rights to the product, taking over all existing business and market authorizations worldwide, including in the United States.

The brand is currently marketed by business partners in several EU countries and Taiwan.Adalvo will assume supply responsibilities for these partners to maintain their business continuity.

Anil Okay, Chief Executive Officer of Adalvo, commented: "This acquisition paves the way for Adalvo's transformational journey. It is a truly disruptive brand. We are excited to enter the brand's offerings and strengthen ourGlobal Partner of Choice status. We will actively maintain our relentless commitment to the partner network we serve to advance our business. We will continue to introduce high-value assets to our product portfolio, which currently also includes branded products."

About Adalvo

Adalvo is a global pharmaceutical company and one of Europe's leading B2B pharmaceutical companies, with business relationships with more than 90 business partners in more than 70 countries around the world.The company's stated purpose is to improve the health of patients around the world, driven by an intelligent collaborative network and a commitment to provide partners with high-quality differentiated products and services.The company is headquartered in Malta and has offices in 15 countries including Switzerland, United Kingdom, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Portugal, Czech Republic and India.Adalvo understands its partners' desire to be bigger, better, and smarter in the dynamic pharmaceutical field, and uses a partner-tailored approach to help disrupt the status quo and help partners achieve their business goals.Whether it's increasing revenue or entering new markets, we pride ourselves on helping our partners achieve their goals.In addition to making partners a high priority, Adalvo is committed to its purpose and mission of accelerating the growth and development of its employees and local communities.Adalvo strives for excellence in everything he does, and is driven by a lasting passion to bring positive improvement to its partners.The company's purpose-driven culture is dedicated to improving the lives of patients around the world.Our dynamic leadership team has the experience and industry expertise to help build the company into a reliable global partner.